call 1800 257 600 email [email protected]

Histiocytic Disorders (H Group)

Histiocytic disorders are a group of rare disorders characterised by the abnormal accumulation of histiocytes, a type of immune cell often found in tissues that regulates immune functions. There are three primary types of histiocytes, including monocytes (plays a role in inflammatory and anti-inflammatory responses during an immune response), macrophages (responsible for ingesting and eliminating foreign substances during an immune reaction), and dendritic cells (initiate and regulate the adaptive immune response).

Histiocytic disorders are broadly classified into five different groups: L groupC groupM groupR group, and H group. The L group, or Langerhans group, are classified as diseases involving Langerhans cells (an immune cell responsible for initiating an immune response when coming into contact with a foreign material), such as Langerhans cell histiocytosis (LCH). The C group, also known as cutaneous and mucocutaneous non-Langerhans cell histiocytosis, are classified as non-Langerhans cell histiocytic disorders that are localised to the skin or mucosal surfaces, such as the mouth, nose, and gastrointestinal system. The M group, also known as malignant histiocytic disorders, are classified by the presence of malignant cells within the tumour(s). The R group, also known as Rosai-Dorfman disease and miscellaneous non-cutaneous non-Langerhans cell histiocytosis or sinus histiocytosis, are classified as non-Langerhans histiocytic disorders that often involve lymph nodes. The H group, also known as hemophagocytic lymphocytosis and macrophage activation syndrome, is composed entirely of hemophagocytic lymphohistiocytosis, a rare and aggressive disease caused by the overactivation of the immune system.

This page will focus specifically on H group histiocytic disorders, which is composed of hemophagocytic lymphohistiocytosis (HLH), also known as macrophage activation syndrome. HLH is a rare, life-threatening condition caused by excess production of histiocytes and lymphocytes, which accumulates and damages organs. While HLH is not cancerous, it is equally as serious.

H group histiocytic disorders are diagnosed equally among the sexes, and tends to be diagnosed before 18 months of age. However, anyone can develop this disease.

Treatment

Each patient with a H group histiocytic disorder will present with a unique disease behaviour, with varying locations, and symptoms. As such, there is no one treatment method that will work for everyone, and there is no standard staging system for this disease.  Instead of staging and grading, your doctor will recommend a treatment plan based on the following factors:

  • Tumour location.
  • Whether or not the tumour(s) have spread.
  • Your age.
  • General health.
  • Treatment preferences.

Your doctor may recommend genetic testing, which analyses your tumour DNA and can help determine which treatment has the greatest chance of success. Your doctor will discuss the most appropriate course of treatment for you.

Treatment options for an H group histiocytic disorder may include:

  • Corticosteroids.
  • Chemotherapy.
  • Immunosuppressive medication.
  • Immunotherapy.
  • Antibiotics.
  • Antiviral medication.
  • Stem cell transplant.
  • Clinical trials.
  • Palliative care.

Risk factors

While the cause of HLH remains unknown, the following factors may increase the likelihood of developing of the disease:

  • Having a family history of HLH.
  • Certain genetic mutations, potentially including:
    • PRF1 gene.
    • UNC13D gene.
    • STX11 gene.
    • STXBP2 gene.
  • Having certain genetic disorders, such as:
    • Griscelli syndrome type 2.
    • Chediak-Higashi syndrome.
    • X-linked lymphoproliferative disorder.
    • XMEN disease.
    • Interleukin-2-inductible T cell kinase deficiency.
    • CD27 deficiency.
    • Hermansky-Pudlak syndrome.
    • Lysinuric protein intolerance.
    • Chronic granulomatous.
  • Viral infections, such as the Epstein-Barr virus.
  • Bacterial infections.
  • Viral infections.
  • Fungal infections.
  • Parasitic infections.
  • Being immunocompromised.
  • Autoimmune diseases.
  • Autoinflammatory diseases.
  • Rheumatological diseases, such as:
    • Systemic juvenile idiopathic arthritis.
    • Systemic lupus erythematosus.
    • Vasculitis.
  • Metabolic disorders.
  • Having cancer, such as:
    • Lymphomas (especially non-Hodgkin lymphoma).
    • Leukaemias.
    • Myeloid neoplasms.

Not everyone with these risk factors will develop the disease, and some people who have the disease may have none of these risk factors. See your general practitioner (GP) if you are concerned.

Symptoms

Symptoms of HLH may include:

  • Fever.
  • Splenomegaly.
  • Cytopenia, such as:
    • Anaemia.
    • Neutropenia.
    • Thrombocytopenia.
  • Hepatomegaly.
  • Lymphadenopathy.
  • Jaundice.
  • Skin rashes.
  • Lung problems, such as:
    • Coughing.
    • Dyspnea.
    • Shortness of breath.
  • Digestive problems, such as:
    • Abdominal pain.
    • Vomiting.
    • Diarrhoea.
  • Headaches.
  • Difficulties walking.
  • Changes in vision.
  • General feeling of weakness and/or unwell.
  • Easy bruising.
  • Swollen and/or bleeding gums.
  • Seizures.
  • Difficulties with coordination.
  • Paralysis on one side of the body (hemiplegia).
  • Anorexia.
  • Irritability.
  • Failure to thrive.
  • Fatigue.

Not everyone with the symptoms above will have cancer, but see your general practitioner (GP) if you are concerned.

Diagnosis

If your doctor suspects you have a H group histiocytic disorder, they may order the following tests to confirm the diagnosis and refer you to a specialist for treatment:

  • Physical examination.
  • Neurological examination.
  • Blood tests.
  • Bone marrow aspiration.
  • Biopsy.

References

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.